{"id":945235,"date":"2026-03-18T07:03:09","date_gmt":"2026-03-18T11:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/"},"modified":"2026-03-18T07:03:09","modified_gmt":"2026-03-18T11:03:09","slug":"kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/","title":{"rendered":"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026"},"content":{"rendered":"

<\/p>\n

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026<\/b><\/p>\n

FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE<\/a>)–
\nKalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company\u2019s eight months fiscal year 2025 financial results and provide a corporate update.<\/p>\n

\nThe live audio webcast will be accessible on the Investors section of the Company\u2019s website at www.ir.kalvista.com\/event-calendar<\/a>. An archived replay will be available on the site approximately two hours after completion of the event.<\/p>\n

About KalVista Pharmaceuticals, Inc.
\n
<\/b>KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY\u00ae\u2014the first and only oral on-demand treatment for hereditary angioedema (HAE)\u2014and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com<\/a> and follow us on LinkedIn<\/a>, X<\/a>, Facebook<\/a> and Instagram<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260318443230\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
Ryan Baker
\n
Head, Investor Relations
\n
(617) 771-5001
\n
ryan.baker@kalvista.com
\n<\/a><\/p>\n

Media:
\n<\/b>
Molly Cameron
\n
Sr. Director, Corporate Communications
\n
(857) 356-0164
\n
molly.cameron@kalvista.com<\/a><\/p>\n

KEYWORDS:<\/b> Europe United States United Kingdom North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Pharmaceutical Research<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)– KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company\u2019s eight months fiscal year 2025 financial results and provide a corporate update. The live audio webcast will be accessible on the Investors section of the Company\u2019s website at www.ir.kalvista.com\/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet … <\/p>\n

Continue reading “KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945235","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)– KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company\u2019s eight months fiscal year 2025 financial results and provide a corporate update. The live audio webcast will be accessible on the Investors section of the Company\u2019s website at www.ir.kalvista.com\/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet … Continue reading "KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T11:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026\",\"datePublished\":\"2026-03-18T11:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/\"},\"wordCount\":251,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/\",\"name\":\"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-03-18T11:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/","og_locale":"en_US","og_type":"article","og_title":"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Market Newsdesk","og_description":"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)– KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company\u2019s eight months fiscal year 2025 financial results and provide a corporate update. The live audio webcast will be accessible on the Investors section of the Company\u2019s website at www.ir.kalvista.com\/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet … Continue reading \"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T11:03:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026","datePublished":"2026-03-18T11:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/"},"wordCount":251,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/","name":"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-03-18T11:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260318443230r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945235"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945235\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}